Clinical Trial Update: Nebulized RNS60 for the Treatment of Amyotrophic Lateral Sclerosis [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating nebulized RNS60 for Amyotrophic Lateral Sclerosis has been withdrawn from ClinicalTrials.gov.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Amyotrophic Lateral Sclerosis

Drugs mentioned

• RNS60

Snippet

Sponsor: Revalesio Corporation | Conditions: Amyotrophic Lateral Sclerosis | Phase 2 | Status: WITHDRAWN